Clinical Trials
Below are current clinical trials.
273 studies in Infectious Diseases Research (all studies, either open or closed).
Filter this list of studies by location, status and more.
-
Rochester, Minn.
The purpose of this study is to test (in 2 stages) the safety/tolerability, pharmacokinetics (how the body handles study drug) and pharmacodynamics (effects on the immune system and the virus) of the study drug ABBV-181 in HIV-1 infected participants undergoing antiretroviral therapy (ART) interruption.
-
Rochester, Minn.
The purpose of this study is to assess influenza vaccine effectiveness (VE) in preventing pandemic influenza virus illness and infection, and to assess the incidence of pandemic influenza virus infection and illness among Health care providers (HCP), first responders (FR) (police, fire, and Emergency Medical Technicians [EMT]) and school personnel (SP).
-
Scottsdale/Phoenix, Ariz.
This is a Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum Microbiota® (CP101) in Subjects with Recurrence of Clostridium difficile Infection (PRISM3)
-
Rochester, Minn.
The purpose of this study is to evaluate the effectiveness, safety and tolerability of Oral Full-Spectrum MicrobiotaTM (CP101) in subjects with recurrence of Clostridium difficile infection.
-
Rochester, Minn.
The purpose of this study is to:
-
To determine the prevalence of MBL in patients with chronic hepatitis C who are to begin therapy with DAA, and compare with clinic controls who are seen in the general medicine clinic at Mayo Clinic
-
To determine the correlation between the specific subtype of MBL (CD5- MBL, atypical CLL-phenotype MBL and CLL-phenotype MBL) relative to the HCV genotype
-
To assess the proportion of individuals with MBL who have an improvement in the circulating monoclonal B-cell population following therapy with DAA
-
Rochester, Minn., Scottsdale/Phoenix, Ariz.
A Phase 3b, single arm, open-label, multicenter study to evaluate the safety and to demonstrate the non-inferiority of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with the glecaprevir (GLE)/pibrentasvir (PIB) combination regimen to the historical SVR12 rate of 12 weeks of treatment with the GLE/PIB in treatment-naïve adults with chronic HCV GT 1, 2, 4, 5, or 6 infection and compensated cirrhosis.
-
Rochester, Minn.
The purpose of this study is to explore lay understandings toward participating in and perceptions of consent to biospecimen research and valuation of genetics in SARS-COV-2 infection, testing, immunity, and vaccine development, to explore professional attitudes toward and perception of barriers and facilitators for implementating genetic technology to facilitate understanding of SARS-COV-2 infection and immunity, improvement and scale-up of testing, and vaccine development, and to identify ethical, social, and inter-professional aspects of microbial genetic technology implementation in population health surveillance, clinical test development, and vaccine research.We hypothesize that engagement with individuals whom directly experience and/or are impacted by the increasing use of SARS-Cov-2 genetic technology, including COVID-19 Pandemic Response Biobank contributors and interdisciplinary expert teams will help identify ethical and social issues in adopting and implementing emerging technology.
-
Rochester, Minn., Jacksonville, Fla.
The purpose of this study is to assess the experience of low income pregnant women at an inner-city health system with seeking and receiving care.
Significant disparities in health care and birth outcomes are seen in the US during normal times. During COVID-19, limited access to health care resources, social distancing and stay at home orders, and shortages of food and other necessities may exacerbate these disparities.
-
Rochester, Minn.
The objective of this study is to evaluate the impact of the Alere™ PBP2a test combined with pharmacist review of antimicrobial therapy, on clinical outcomes and cost in hospitalized patients with sterile site S. aureus infection.
-
Rochester, Minn.
This clinical trial is studying biomarkers in diagnosing cervical lesions in patients with abnormal cervical cells. Studying biomarkers in abnormal cervical cells may improve the ability to find cervical lesions and plan effective treatment.